Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of TNF blockade on effector T-cell populations in rheumatoid arthritis
2009-012424-87Phase 4Completed
- Sponsor
- Imperial College London
- Start
- Oct 2009
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of etanercept and adalimumab in rheumatoid arthritis (RA) (2 arms), sponsored by Imperial College London. Primary endpoint: Immunologic biomarker endpoint. Started Oct 2009; status: completed.
02
Drugs
etanerceptadalimumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2009-012424-87.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012424-87.